Adaptive Biotechnologies Stock Fair Value – Putnam Investments LLC Reduces Investment in Adaptive Biotechnologies Co. in 2023.
March 17, 2023
Trending News 🌥️
Adaptive Biotechnologies ($NASDAQ:ADPT) Co. has experienced a substantial decrease in its stake held by Putnam Investments LLC after 2023. Putnam Investments LLC, a prominent asset management company, has significantly reduced their investment in the biotechnology enterprise. This news has come as a surprise to many investors due to the fact that Adaptive Biotechnologies Co. has been a lucrative business. The company is known for its innovative approach to genetic science and providing groundbreaking treatments to patients. Despite the reduction in stake, Adaptive Biotechnologies Co. continues to be a popular choice among investors. The company has seen steady growth since its inception and remains one of the most respected companies in its sector. Although Putnam Investments LLC has reduced its stake in the company, it is still one of the leading shareholders. This is because they believe that Adaptive Biotechnologies Co. will continue to be a major player in the biotechnology industry and could offer great returns on investments in the future.
However, the company continues to demonstrate its commitment to innovation and growth. Despite the decrease in stake, it has shown no signs of slowing down and is continuing to develop groundbreaking treatments and therapies for patients around the world. It is clear that Adaptive Biotechnologies Co. is still a promising business and will likely remain so for many years to come.
Stock Price
On Wednesday, Adaptive Biotechnologies Co. experienced a slight surge in their stock prices as the prices opened at $7.9 and closed at $8.2, up by 1.0% from last closing price of 8.1. Unfortunately, after experiencing a surge of investors in the beginning of 2023, Putnam Investments LLC has announced that they have taken a step back and have reduced their investment in Adaptive Biotechnologies Co. Although it is unclear as to why they have done this, the reduction in investment has had an effect on the overall stock prices of the company. However, the company remains optimistic that they will be able to make up for the lost investment by attracting more investors in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adaptive Biotechnologies. More…
| Total Revenues | Net Income | Net Margin |
| 185.31 | -200.19 | -108.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptive Biotechnologies. More…
| Operations | Investing | Financing |
| -183.94 | 2.9 | 132.26 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptive Biotechnologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 856.62 | 392.52 | 3.24 |
Key Ratios Snapshot
Some of the financial key ratios for Adaptive Biotechnologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 29.6% | – | -105.8% |
| FCF Margin | ROE | ROA |
| -108.1% | -25.8% | -14.3% |
Analysis – Adaptive Biotechnologies Stock Fair Value
At GoodWhale, we take great pride in analyzing the fundamentals of ADAPTIVE BIOTECHNOLOGIES. After running our proprietary Valuation Line, we have determined that the intrinsic value of their share is around $42.2. This means that the current price of $8.2 represents a massive 80.6% discount! Our team of analysts believes that this presents an incredible opportunity for investors to purchase an undervalued stock. Now is the time to take advantage of this potential bargain and invest in ADAPTIVE BIOTECHNOLOGIES. More…
Peers
Adaptive Biotechnologies Corp is a biotechnology company that develops products to diagnose and treat cancer and other diseases. The company’s products are based on its proprietary technology platforms, which enable the company to identify and target cancer cells and other diseased cells. The company’s products include diagnostic tests and treatments for cancer, autoimmune diseases, and infectious diseases.
The company’s main competitors are Forte Biosciences Inc, Synaptogenix Inc, and Resverlogix Corp.
– Forte Biosciences Inc ($NASDAQ:FBRX)
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics to improve patient outcomes in dermatology and immunology. The company’s lead product candidate is Vixari, a topical formulation of an anti-TNF-alpha biologic, which is in Phase 2 clinical trials for the treatment of plaque psoriasis. Forte Biosciences has a market cap of 20.95M as of 2022 and a Return on Equity of -42.75%. The company’s focus on developing therapeutics to improve patient outcomes in dermatology and immunology makes it a promising investment opportunity in the healthcare sector.
– Synaptogenix Inc ($NASDAQ:SNPX)
Synaptogenix is a clinical-stage biotechnology company developing drugs to treat neurodegenerative diseases. The company’s lead product candidate, SYN-115, is in development for the treatment of Alzheimer’s disease. Synaptogenix has a market cap of $43.23 million as of 2022 and a return on equity (ROE) of -38.9%. The company’s clinical-stage drugs are not yet approved for commercial use, which makes it a high-risk investment. However, the potential rewards for investors are significant if Synaptogenix is successful in developing an effective treatment for Alzheimer’s disease.
– Resverlogix Corp ($TSX:RVX)
Resverlogix Corp. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of atherosclerosis and associated diseases. Its products include RVX-208, RVX-210, and BETonMACE. The company was founded by Norman W. Wong on February 3, 2004 and is headquartered in Calgary, Canada.
Summary
Adaptive Biotechnologies is a leading biomedical technology company focused on developing tests to track and interpret changes in the immune system. In 2023, Putnam Investments LLC, a large investment firm, has reduced its investment in Adaptive Biotechnologies. This is likely due to the company’s failure to meet expected performance targets or because Putnam may have shifted its focus to other investments. Despite this, investors remain optimistic about Adaptive Biotechnologies’ prospects, citing their innovative technology and potential for long-term growth.
The company is currently making strides in developing a diagnostic platform to detect cancer, autoimmune and infectious diseases, and researchers are exploring the use of their technology to develop a new generation of vaccines. With increasing investments from other venture capital firms and partnerships with leading pharmaceutical companies, Adaptive Biotechnologies looks set for further growth in the coming years.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
